Clinical actionability

In one sentence

Clinical actionability asks whether a finding supports a specific medical decision in the relevant disease and treatment setting.

The intuition

A molecular match is the beginning of a question. It names a finding and perhaps a drug class. The full answer also needs reliable measurement, evidence of benefit, clinical eligibility and a feasible, safe intervention. Those are separate gates.

How it works

An analytical validation establishes how an assay measures its intended quantity. Clinical validity relates that measurement to a condition or outcome. Clinical utility asks whether using the information improves a meaningful decision or outcome. A laboratory’s quality certification is not a universal guarantee of treatment benefit.

Research-use-only (RUO) measurements can support hypotheses and experiments. Clinical laboratory standards concern testing quality and scope. FDA-cleared or approved companion diagnostics have a specified intended use linked to a therapy; another assay or gene result is not automatically interchangeable.

Evidence frameworks such as ESCAT rank the strength of clinical evidence for a target–drug match. OncoKB annotations also depend on cancer and setting. A database tier, a pathogenicity prediction and a trial’s inclusion criterion describe different claims. The actual source and version matter.

A drug approved for one cancer or biomarker can remain investigational for another. Likewise, a tumor-only BRCA alteration can support a research question while failing a breast-cancer adjuvant label requiring a germline variant. Feasibility adds current eligibility, availability, formulation, tissue requirements and clinical safety. High-quality mechanistic evidence cannot bypass these gates.

Why it matters in cancer

It makes the intended decision explicit before a molecular match is treated as a clinical option.

Worked example

A genomic scar suggests past repair deficiency. The proposed medicine has an adjuvant label requiring a qualifying germline BRCA variant. The scar does not satisfy that label. A trial or expert-reviewed off-label question would need its own evidence, rather than being described as automatically on-label.

Common confusions

Pathogenicity is not drug sensitivity.
CLIA certification does not establish predictive utility for every reported assay.
Target engagement, tumor response and survival benefit are distinct outcomes.

Biomarker evidence and five clinical gates.

Vocabulary: HRD means homologous recombination deficiency.

Sources and scope

General teaching, source-checked October 8, 2026. The examples are hypothetical unless a study is explicitly named. Expert and learner review remain pending.